Try our mobile app

General information

Country: UNITED STATES

Sector: Drug Manufacturers — General

AbbVie Inc. researches and develops pharmaceutical products. The Company produces pharmaceutical drugs for specialty therapeutic areas such as immunology, chronic kidney disease, hepatitis C, women"s health, oncology, and neuroscience. AbbVie also offers treatments for diseases including multiple sclerosis, parkinson"s, and alzheimer"s disease.
Website: abbvie.com


  • Good financial results growth rate 14.1% (average between last period year over year growth for revenue and EBITDA), there is acceleration compared to average historical growth rates (-7.9%)
  • Dividend yield for the last twelve months 2.9%
  • Free cash flow yield -1.6% (LTM)
  • Share price is 69.9% higher than minimum and 7.9% lower than maximum for the last 3 years
  • The company is overvalued by EV / LTM EBITDA multiple compared to target level (39.5x vs
    )
  • Fundamental value created in LTM (estimate)
  • For the last 3 months insiders sold company shares on $11.0 mln (-0.003% of cap.)

Key Financials (Download financials)

Ticker: ABBV
Share price, USD:  (-1.1%)225.14
year average price 194.71  


year start price 201.50 2024-10-30

min close price 164.99 2024-11-15

max close price 244.38 2025-10-01

current price 225.14 2025-10-30
Common stocks: 1 768 480 508

Dividend Yield:  2.9%
FCF Yield LTM: -1.6%
EV / LTM EBITDA: 39.5x
EV / EBITDA annualized: 22.7x
Last revenue growth (y/y):  +6.6%
Last growth of EBITDA (y/y):  +21.5%
Historical revenue growth:  +0.7%
Historical growth of EBITDA:  -16.5%
Target EV / EBITDA (hist percentile):
Express share price potential:
Fundamental value created in LTM:
EV / LTM EBITDA mutiple calculation
Market Cap ($m): 398 156
Net Debt ($m): 64 059
EV (Enterprise Value): 462 215
EBITDA LTM ($m): 11 713
EV / LTM EBITDA: 39.5x
Price to Book: 66.7x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / EBITDA

Potential dynamics

News


2025-10-29prnewswire.com

AbbVie Announces Positive Topline Results from Phase 3 Pivotal Studies Evaluating Upadacitinib (RINVOQ®) in Adults and Adolescents with Vitiligo

2025-10-28zacks.com

Should You Buy AbbVie Stock Ahead of Q3 Earnings Report?

2025-10-27zacks.com

What's in Store for These 5 Pharma Bigwigs This Earnings Season?

2025-10-21zacks.com

This 3 Stocks Portfolio Provides Monthly Income

2025-10-20zacks.com

Here's What to Expect From AbbVie's Oncology Segment in Q3 Earnings

2025-10-17seekingalpha.com

AbbVie: "Strong Buy" On Rinvoq Expansions And Immunology Pipeline Addition

2025-10-14zacks.com

Can Rinvoq and Skyrizi Sales Drive Another Strong Quarter for AbbVie?

2025-10-13prnewswire.com

AbbVie to Present New Data at ESMO 2025 Reinforcing Leadership in Advancing Targeted Therapies for Solid Tumors

2025-10-09zacks.com

AbbVie vs. Eli Lilly: Which Large Drugmaker Has the Edge in 2025?

2025-10-08marketbeat.com

Why AbbVie and Johnson & Johnson Could Outperform Pfizer
More information for subscribed users:
detailed calculation of
Potential and Created Value,
website traffic data